Coherus Awaits August 2022 Date As FDA Accepts Ranibizumab Biosimilar
Company Set For Showdown With Samsung Bioepis For Biosimilar Lucentis
Executive Summary
The US FDA has accepted for review the CHS-201 Lucentis biosimilar product developed by Formycon/Bioeq that is to be sold in the US by Coherus BioSciences, shortly after approving the first ranibizumab biosimilar to treat wet age-related macular degeneration.